Adverse events
| Adverse event . | Grade 3 . | Grade 4 . |
|---|---|---|
| No. (%) . | No. (%) . | |
| Blood and lymphatic system | 2 (3) | 0 |
| Cardiac | 4 (5) | 1 (1) |
| Coagulation | 1 (1) | 1 (1) |
| Gastrointestinal | 6 (8) | 1 (1) |
| Hepatic | 3 (4) | 0 |
| Infection/febrile neutropenia | 6 (8) | 3* (4) |
| Neurologic | 3 (4) | 0 (0) |
| Pulmonary/respiratory | 6 (8) | 2* (3) |
| Renal and urinary disorder | 7 (9) | 2 (3) |
| Secondary cancer | 1 (1) | 0 |
| Adverse event . | Grade 3 . | Grade 4 . |
|---|---|---|
| No. (%) . | No. (%) . | |
| Blood and lymphatic system | 2 (3) | 0 |
| Cardiac | 4 (5) | 1 (1) |
| Coagulation | 1 (1) | 1 (1) |
| Gastrointestinal | 6 (8) | 1 (1) |
| Hepatic | 3 (4) | 0 |
| Infection/febrile neutropenia | 6 (8) | 3* (4) |
| Neurologic | 3 (4) | 0 (0) |
| Pulmonary/respiratory | 6 (8) | 2* (3) |
| Renal and urinary disorder | 7 (9) | 2 (3) |
| Secondary cancer | 1 (1) | 0 |
Grade 1 to 2 events were not recorded in this trial. All grade 3 and 4 adverse events are shown.
Includes 1 patient in each category who experienced a grade 5 fatal event due to pneumonia and multiorgan failure due to sepsis.